Raymond James & Associates’s Cross Country Healthcare CCRN Stock Holding History

Raymond James & Associates’s Portfolio CCRN Stock Details CCRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-165,324	Closed	-$2.29M	–	4011
2024 Q2	$2.29M	Buy	165,324 +1,155	+0.7%	+$18.3K	﹤0.01%	2075
2024 Q1	$3.07M	Buy	164,169 +24,165	+17%	+$483K	﹤0.01%	1900
2023 Q4	$3.17M	Buy	140,004 +55,428	+66%	+$1.2M	﹤0.01%	1818
2023 Q3	$2.1M	Buy	+84,576	New	+$2.13M	﹤0.01%	1994
2023 Q2	–	Sell	-21,387	Closed	-$477K	–	3849
2023 Q1	$477K	Sell	21,387 -36,467	-63%	-$955K	﹤0.01%	2940
2022 Q4	$1.54M	Sell	57,854 -263	-0.5%	-$8.58K	﹤0.01%	2170
2022 Q3	$1.65M	Buy	58,117 +12,955	+29%	+$333K	﹤0.01%	2092
2022 Q2	$941K	Sell	45,162 -11,325	-20%	-$212K	﹤0.01%	2484
2022 Q1	$1.22M	Sell	56,487 -900	-2%	-$19.5K	﹤0.01%	2462
2021 Q4	$1.59M	Buy	+57,387	New	+$1.39M	﹤0.01%	2321

Other funds holding CCRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

SFM

Systematic Financial Management Teaneck, New Jersey $4.36B AUM 40.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

ACB

Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Raymond James & Associates's CCRN Position: Q3 2024 in Review

Raymond James & Associates sold out of Cross Country Healthcare (CCRN) in Q3 2024, closing a stake of 165,324 shares — an estimated $2.29M sold.

Raymond James & Associates first reported a position in CCRN in Q4 2021 and held it in 10 quarters. The position peaked at $3.17M in Q4 2023. 180 funds tracked by Wall St. Rank hold CCRN as of Q3 2024.

Raymond James & Associates reported no remaining Cross Country Healthcare position as of Q3 2024 after selling out during the quarter.
Raymond James & Associates sold 165,324 Cross Country Healthcare shares in Q3 2024, an estimated $2.29M.
Raymond James & Associates first reported a position in Cross Country Healthcare in Q4 2021 and held it in 10 quarters.
Raymond James & Associates's Cross Country Healthcare position peaked at $3.17M in Q4 2023.
180 funds tracked by Wall St. Rank held Cross Country Healthcare as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.